Association of Urine Galectin-3 With Cardiorenal Outcomes in Patients With Heart Failure.
J Card Fail
; 30(2): 340-346, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-37301248
ABSTRACT
BACKGROUND AND OBJECTIVES:
Approaches to distinguishing pathological cardiorenal dysfunction in heart failure (HF) from functional/hemodynamically mediated changes in serum creatinine are needed. We investigated urine galectin-3 as a candidate biomarker of renal fibrosis and a prognostic indicator of cardiorenal dysfunction phenotypes.METHODS:
We measured urine galectin-3 in 2 contemporary HF cohorts the Yale Transitional Care Clinic (YTCC) cohort (nâ¯=â¯132) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial (nâ¯=â¯434). We assessed the association of urine galectin-3 with all-cause mortality in both cohorts and the association with an established marker of renal tissue fibrosis, urinary amino-terminal propeptide of type III procollagen (PIIINP) in TOPCAT.RESULTS:
In the YTCC cohort, there was significant effect modification between higher urine galectin-3 and lower estimated glomerular filtration rates (eGFRs) (Pinteractionâ¯=â¯0.046), such that low eGFR levels had minimal prognostic importance if urine galectin-3 levels were low, but they were important and indicated high risk if urine galectin-3 levels were high. Similar observations were noted in the TOPCAT study (Pinteractionâ¯=â¯0.002). In TOPCAT, urine galectin-3 also positively correlated with urine PIIINP at both baseline (râ¯=â¯0.43; P < 0.001) and at 12 months (râ¯=â¯0.42; P < 0.001).CONCLUSIONS:
Urine galectin-3 levels correlated with an established biomarker of renal fibrosis in 2 cohorts and was able to differentiate high- vs low-risk phenotypes of chronic kidney disease in HF. These proof-of-concept results indicate that additional biomarker research to differentiate cardiorenal phenotypes is warranted.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Insuficiência Cardíaca
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J Card Fail
Assunto da revista:
CARDIOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos